XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction
Benzinga Newsdesk 10 months ago
BiotechNewsHealth CareContractsGeneral
Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reducedXOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of
- Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced
- XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda's externalized assets portfolio.
- Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079)
- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio